CrisBio® technology can be swiftly adapted to the large-scale manufacturing of various HA antigens or in combination with other influenza antigens such as NA (some experimental long-lasting immunity vaccines are under evaluation [26]), enabling the deployment of seasonal and pandemic influenza vaccines within approximately three months, a marked improvement over the 6 to 8 months required using fertile egg technology. Here, XK is linked to influenza.